Sung H W, Kuo D P, Shu W P, Chai Y B, Liu C C, Li S M
J Bone Joint Surg Am. 1982 Jun;64(5):755-61.
Giant-cell tumor of bone seems to occur more frequently in Chinese people than in those residing in Western countries. The estimated incidence is about 20 per cent of all primary tumors of bone. Of 208 surgically treated and pathologically proved giant-cell tumors, 194 were benign. We excluded patients with primary or secondary amputation unrelated to recurrence and those followed for less than two years or lost to follow-up. Of the remaining 111 patients who were followed for more than two years, twenty-nine had a recurrence, giving a recurrence rate of 26.1 per cent. The rate of recurrence was highest following curettage and bone-grafting (41.2 per cent) and was much lower in patients who were treated by resection and fusion (7.1 per cent). Since resection of this tumor with reconstructive procedures, either by massive homogenous bone-grafting or artificial joint replacement, is complicated and might cripple the patient if it fails, we propose excision and curettage with bone-grafting as the most suitable method of treatment in the majority of patients with giant-cell tumor of bone.
骨巨细胞瘤在中国人群中的发病率似乎高于西方国家人群。据估计,其发病率约占所有原发性骨肿瘤的20%。在208例接受手术治疗并经病理证实的骨巨细胞瘤患者中,194例为良性。我们排除了与复发无关的原发性或继发性截肢患者,以及随访时间不足两年或失访的患者。在其余111例随访时间超过两年的患者中,有29例复发,复发率为26.1%。刮除植骨后的复发率最高(41.2%),而接受切除融合治疗的患者复发率则低得多(7.1%)。由于采用重建手术切除该肿瘤,无论是通过大块同种异体骨移植还是人工关节置换,都很复杂,且如果失败可能会使患者致残,因此我们建议,对于大多数骨巨细胞瘤患者,切除刮除植骨是最合适的治疗方法。